Showing results (501-510 of 592) with videos related to
Sort By:
Pageof 60
Acta Oncologica (Stockholm, Sweden)|May 19, 2025
Simultaneous integrated boost intensity-modulated radiotherapy for treatment of bone metastases: analysis of a breast cancer cohortFabio Marazzi, Valeria Masiello, Alessandra Fabi, et al.European Journal of Cancer (Oxford, England : 1990)|July 5, 2021
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trialValentina Guarneri, Carlo Alberto Giorgi, Saverio Cinieri, et al.Critical Reviews in Oncology/Hematology|December 13, 2021
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific SocietiesAntonio Russo, Lorena Incorvaia, Ettore Capoluongo, et al.Plos One|November 14, 2019
Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approachAlessio Bruni, Niccolò Giaj-Levra, Patrizia Ciammella, et al.NPJ Breast Cancer|December 13, 2025
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancerEmma Zattarin, Antonio Marra, Antonella Palazzo, et al.Journal of the National Cancer Institute|December 28, 2022
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1Fara Brasó-Maristany, Gaia Griguolo, Nuria Chic, et al.Cancers|July 18, 2020
ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast CancerGaia Griguolo, Fara Brasó-Maristany, Blanca González-Farré, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerMarion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.NPJ Breast Cancer|August 16, 2025
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Consortium analysisLetizia Pontolillo, Andrew A Davis, Lorenzo Gerratana, et al.Journal of the National Cancer Institute|March 28, 2026
Temporal Patterns and Factors Associated with Early Termination in Phase 1 Clinical Trials for Solid TumorsGiovanni Maria Iannantuono, Stefano Sganga, Tommaso Giovagnoli, et al.Pageof 60